Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
9.16% $2.98
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 4.43 mill |
EPS: | -24.40 |
P/E: | -0.120 |
Earnings Date: | Mar 30, 2024 |
SharesOutstanding: | 1.486 mill |
Avg Daily Volume: | 0.0819 mill |
RATING 2024-03-28 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.120 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.02x |
Company: PE -0.120 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.445 (-85.07%) $-2.54 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 2.34 - 3.62 ( +/- 21.51%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-18 | Berger Mark Stanley | Sell | 1 319 | Common Stock |
2024-02-18 | Varner John Rodney | Sell | 2 642 | Common Stock |
2024-02-18 | Confer Ryan M. | Sell | 1 126 | Common Stock |
2023-06-27 | Moreno Toscano Jose Antonio | Buy | 123 795 | Common Stock |
2023-06-27 | Longnecker Brent M | Buy | 123 795 | Common Stock |
INSIDER POWER |
---|
95.21 |
Last 87 transactions |
Buy: 12 465 411 | Sell: 3 375 631 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.98 (9.16% ) |
Volume | 0.0295 mill |
Avg. Vol. | 0.0819 mill |
% of Avg. Vol | 36.01 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.